07.13.26 -- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale

Tech transfer missteps risk higher costs and lower product quality. Success hinges on a clear sponsor strategy and working with an experienced, collaborative CDMO.

Advanced therapy success depends on early quality integration, effective tech transfer, data integrity, and aligned teams to ensure scalable, compliant manufacturing.

Single-cell sequencing and flow cytometry jointly map T-cell function and safety attributes. Evaluate how this precise analytical data guides development and improves quality control.

Funding shifts and evolving therapeutic pipelines are actively altering CDMO capacity. Assess how upcoming market competition and strategic realignments will impact your outsourcing model.

Choosing the wrong ligand binding assay platform early in drug development can cost you time, data quality, and regulatory standing. Learn what actually drives platform selection for biologics.

Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.

Discover why this area is poised to become a leading hub for cell and gene therapy, as highlighted by CCS and industry experts at the 6th Annual Supply Chain Summit.